Transaction in Own Shares Transaction in Own Shares 13 May, 2025 • • • • • • • • • • • • • • • • Shell plc (the ‘Company’) announces that on 13 May, 2025 it purchased the following number of Shares for cancellation. Aggregated information on Shares purchased according to trading venue: Date of purchaseNumber of Shares purchasedHighest price paidLowest price paid Volume weighted average price paid per shareVenueCurrency13/05/2025632,622£25.2400£24.8100£25.0313LSEGBP13/05/2025136,868£25.2350£24.8700£25.0297Chi-X (CXE)GBP13/05/202578,510£25.2350£24.8700£25.0440BATS (BXE)GBP13/05/2025532,5...
Transaction in Own Shares Transaction in Own Shares 12 May, 2025 • • • • • • • • • • • • • • • • Shell plc (the ‘Company’) announces that on 12 May, 2025 it purchased the following number of Shares for cancellation. Aggregated information on Shares purchased according to trading venue: Date of purchaseNumber of Shares purchasedHighest price paidLowest price paid Volume weighted average price paid per shareVenueCurrency12/05/2025478,357£25.2650£24.9300£25.0886LSEGBP12/05/2025149,113£25.2500£24.9900£25.0825Chi-X (CXE)GBP12/05/202592,530£25.2250£24.9800£25.0825BATS (BXE)GBP12/05/2025310,5...
Publication of Prospectus Shell International Finance B.V. and Shell plc 12 May 2025 Publication of Prospectus The following prospectus has been approved by the UK Financial Conduct Authority and is available for viewing: Information Memorandum dated 9 May 2025 relating to the Multi-Currency Debt Securities Programme of Shell International Finance B.V. (as Issuer) and Shell plc (as Issuer and as Guarantor) The Information Memorandum constitutes a base prospectus for the purposes of Regulation (EU) 2017/1129 as it forms part of United Kingdom domestic law by virtue of the European Un...
Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States Saint Herblain (France), May, 12 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Association (FDA) and the U.S. Centers for Disease Control and Prevention (CDC), in a joint to the medical community, have recommended a pause in the use of Valneva’s single-dose live attenuated chikungunya vaccine IXCHIQ® in elderly individuals while ongoing investigations into reported serious adverse events (SAEs) are completed. This update f...
Valneva fait un point sur les recommandations d’utilisation d'IXCHIQ® chez les personnes âgées aux États-Unis Saint Herblain (France), le 12 mai 2025 – (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que l’agence de santé américaine Food and Drug Administration (FDA) et les centres américains de contrôle et de prévention des maladies (CDC) ont recommandé à la communauté médicale américaine dans une communication conjointe de suspendre l'utilisation du vaccin vivant atténué à dose unique contre le chikungunya de Valneva, IXCHIQ®, chez les ...
AUCTUS PUBLICATIONS ________________________________________ Panoro Energy (PEN NO)C; Target price of NOK49 per share: ~12 mbbl/d in 1Q25. Re-iterating FY25 guidance – 1Q25 production was ~12 mbbl/d, including 6,841 bbl/d in Gabon, 3,661 bbl/d in Equatorial Guinea and 1,492 bbl/d in Tunisia. Production in Gabon and Equatorial Guinea was previously reported by BW Energy and Kosmos Energy. Equatorial Guinea output was temporarily impacted by unplanned downtime at the Ceiba Cluster, but operations ...
Transaction in Own Shares Transaction in Own Shares 9 May, 2025 • • • • • • • • • • • • • • • • Shell plc (the ‘Company’) announces that on 9 May, 2025 it purchased the following number of Shares for cancellation. Aggregated information on Shares purchased according to trading venue: Date of purchaseNumber of Shares purchasedHighest price paidLowest price paid Volume weighted average price paid per shareVenueCurrency09/05/2025562,249£24.7750£24.4900£24.6411LSEGBP09/05/2025134,097£24.7700£24.4950£24.6459Chi-X (CXE)GBP09/05/2025114,654£24.7700£24.4950£24.6434BATS (BXE)GBP09/05/2025464,52...
Transaction in Own Shares Transaction in Own Shares 8 May, 2025 • • • • • • • • • • • • • • • • Shell plc (the ‘Company’) announces that on 8 May, 2025 it purchased the following number of Shares for cancellation. Aggregated information on Shares purchased according to trading venue: Date of purchaseNumber of Shares purchasedHighest price paidLowest price paid Volume weighted average price paid per shareVenueCurrency08/05/2025606,148£24.4950£24.2000£24.3499LSEGBP08/05/2025155,872£24.4950£24.2000£24.3538Chi-X (CXE)GBP08/05/2025112,980£24.5000£24.2200£24.3888BATS (BXE)GBP08/05/2025499,40...
Transaction in Own Shares Transaction in Own Shares 7 May, 2025 • • • • • • • • • • • • • • • • Shell plc (the ‘Company’) announces that on 7 May, 2025 it purchased the following number of Shares for cancellation. Aggregated information on Shares purchased according to trading venue: Date of purchaseNumber of Shares purchasedHighest price paidLowest price paid Volume weighted average price paid per shareVenueCurrency07/05/2025616,136£24.5300£24.2150£24.3664LSEGBP07/05/2025205,672£24.5400£24.2150£24.3722Chi-X (CXE)GBP07/05/2025118,192£24.5300£24.2250£24.3761BATS (BXE)GBP07/05/2025551,90...
VALNEVA Declaration of shares and voting rights: April 30, 2025 VALNEVA Declaration of shares and voting rights April 30, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: May 7, 2025 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal number of vot...
VALNEVA Déclaration d’actions et de droits de vote : 30 avril 2025 VALNEVA Déclaration d’actions et de droits de vote 30 avril 2025__________________________________________________________________________________________ Dénomination sociale : VALNEVAAdresse du siège social : 6 rue Alain Bombard, 44800 Saint-HerblainMarché réglementé Euronext Paris - Compartiment B Date de la déclaration : 7 mai 2025 Nombre d’actions composant le capital de ValnevaNombre total de droits de vote incluant les droits de vote suspendus*Origine de la variationDate à laquelle cette variation a été constaté...
Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly Saint Herblain (France), May, 07 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) has started a review of Valneva’s single-dose live attenuated chikungunya vaccine IXCHIQ® based on reports of serious adverse events (SAEs) in elderly people. As a temporary measure, while this review is ongoing, EMA has suspended the use of the vaccine for individuals over 65 years old. EMA has maintained current recommendations...
Valneva fait un point suite à l'annonce de l'agence européenne des médicaments sur l'utilisation d'IXCHIQ® chez les personnes âgées Saint Herblain (France), le 07 mai 2025 – (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que l’agence européenne des médicaments (EMA) a entamé une revue du vaccin vivant atténué contre le chikungunya IXCHIQ® de Valneva sur la base de rapports d'effets indésirables graves chez des personnes âgées. À titre de mesure temporaire, l'EMA a suspendu l'utilisation du vaccin pour les personnes âgées de plus de 65 an...
With oil prices approaching USD60/bbl, we believe investors will be looking for E&P exposure with the least risk of cuts to shareholder distributions. We continue to prefer Aker BP, as we consider its dividend safe despite prospects of muted near-term cash flow, and believe it has the most flexibility to adjust capex to protect cash flow and dividends medium-term.
Valneva reported a strong set of Q1 results, with product revenues coming in at EUR 48.6m (vs css 39.1m, +24%), adj EBITDA at EUR (0.6m) (vs css EUR(14.8m)), and a cash position at EUR153m (excl. USD14.2m from the ATM program). Revenues performance were primarily driven by Ixiaro (EUR27.5m), while
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.